Fukamachi et al. found that the Wnt-mTOR pathway is strongly involved in the growth regulation of diffuse GC initiating cells, and based on this, they demonstrated that mTOR inhibitors and checkpoint inhibitors could be useful in treating a subset of diffuse GCs [22]. Here, MTOR is linked to gastric cancer.